NO20002777L - FremgangsmÕte for bekjempelse av fedme - Google Patents

FremgangsmÕte for bekjempelse av fedme

Info

Publication number
NO20002777L
NO20002777L NO20002777A NO20002777A NO20002777L NO 20002777 L NO20002777 L NO 20002777L NO 20002777 A NO20002777 A NO 20002777A NO 20002777 A NO20002777 A NO 20002777A NO 20002777 L NO20002777 L NO 20002777L
Authority
NO
Norway
Prior art keywords
obesity
procedure
combating obesity
treated
diseases
Prior art date
Application number
NO20002777A
Other languages
English (en)
Other versions
NO20002777D0 (no
NO324694B1 (no
Inventor
Klaus Muenter
Michael Kirchengast
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Ag filed Critical Knoll Ag
Publication of NO20002777D0 publication Critical patent/NO20002777D0/no
Publication of NO20002777L publication Critical patent/NO20002777L/no
Publication of NO324694B1 publication Critical patent/NO324694B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20002777A 1997-12-05 2000-05-30 Anvendelse av endotelinreseptor-antagonister for fremstilling av medikamenter for a kontrollere hyperlipidemi. NO324694B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19754082A DE19754082A1 (de) 1997-12-05 1997-12-05 Methode zur Bekämpfung der Fettleibigkeit
PCT/EP1998/007501 WO1999029308A2 (de) 1997-12-05 1998-11-21 Methode zur bekämpfung der fettleibigkeit

Publications (3)

Publication Number Publication Date
NO20002777D0 NO20002777D0 (no) 2000-05-30
NO20002777L true NO20002777L (no) 2000-06-02
NO324694B1 NO324694B1 (no) 2007-12-03

Family

ID=7850913

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20002777A NO324694B1 (no) 1997-12-05 2000-05-30 Anvendelse av endotelinreseptor-antagonister for fremstilling av medikamenter for a kontrollere hyperlipidemi.
NO20074419A NO20074419L (no) 1997-12-05 2007-08-30 Anvendelse av endotelinreseptorantagonister for fremstilling av medikamenter for a bekjempe sykdom

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20074419A NO20074419L (no) 1997-12-05 2007-08-30 Anvendelse av endotelinreseptorantagonister for fremstilling av medikamenter for a bekjempe sykdom

Country Status (17)

Country Link
US (1) US6197780B1 (no)
EP (1) EP1035851B1 (no)
JP (1) JP2002512173A (no)
KR (1) KR20010032779A (no)
CN (1) CN1152685C (no)
AT (1) ATE204172T1 (no)
AU (1) AU751053B2 (no)
BR (1) BR9815335A (no)
CA (1) CA2311423C (no)
CZ (1) CZ300442B6 (no)
DE (2) DE19754082A1 (no)
ES (1) ES2162493T3 (no)
HK (1) HK1037141A1 (no)
HU (1) HUP0100171A3 (no)
NO (2) NO324694B1 (no)
RU (1) RU2292891C2 (no)
WO (1) WO1999029308A2 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
EP1130027A1 (de) * 2000-02-29 2001-09-05 Aventis Pharma Deutschland GmbH Memno-Peptide, Verfahren zu ihrer Herstellung und Verwendung derselben
US20050175667A1 (en) * 2004-02-10 2005-08-11 Wenda Carlyle Use of endothelin antagonists to prevent restenosis
US20090054473A1 (en) 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
CA2855372C (en) * 2011-11-11 2022-03-22 Nimbus Apollo, Inc. 2,4-dioxo-thieno[2,3-d]pyrimidinyl derivatives and pharmaceutical compositions thereof used as acc inhibitors
EA201700155A1 (ru) * 2014-10-20 2017-10-31 Товарищество С Ограниченной Ответственностью "Фармацевтическая Компания "Ромат" Фармацевтическая композиция для лечения туберкулеза
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
WO2017091602A1 (en) 2015-11-25 2017-06-01 Gilead Apollo, Llc Ester acc inhibitors and uses thereof
EA201890910A1 (ru) 2015-11-25 2018-11-30 Джилид Аполло, Ллс ФУНГИЦИДНЫЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 2,4-ДИОКСО-1,4-ДИГИДРОТИЕНО[2,3-d]ПИРИМИДИНА
CN108349995B (zh) 2015-11-25 2021-08-03 吉利德阿波罗公司 吡唑acc抑制剂及其用途
PL3380479T3 (pl) 2015-11-25 2023-05-08 Gilead Apollo, Llc Triazolowe inhibitory acc i ich zastosowania
TWI818828B (zh) 2016-03-02 2023-10-11 美商基利阿波羅有限責任公司 噻吩并嘧啶二酮ａｃｃ抑制劑之固體型式及其製造方法
EP4122464B1 (en) 2017-03-28 2024-05-15 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658924A (en) 1992-12-01 1997-08-19 The Green Cross Corporation 1,8-naphthyridin-2-one derivative and use thereof
US5998468A (en) 1995-08-24 1999-12-07 Warner-Lambert Company Furanone endothelin antagonists
JP3116347B2 (ja) * 1996-11-13 2000-12-11 田辺製薬株式会社 医薬組成物

Also Published As

Publication number Publication date
DE19754082A1 (de) 1999-06-10
BR9815335A (pt) 2000-10-17
RU2292891C2 (ru) 2007-02-10
NO20002777D0 (no) 2000-05-30
CA2311423A1 (en) 1999-06-17
CZ300442B6 (cs) 2009-05-20
EP1035851B1 (de) 2001-08-16
ATE204172T1 (de) 2001-09-15
JP2002512173A (ja) 2002-04-23
ES2162493T3 (es) 2001-12-16
EP1035851A2 (de) 2000-09-20
HUP0100171A3 (en) 2003-10-28
CZ20002006A3 (cs) 2000-11-15
CA2311423C (en) 2008-01-29
RU2003138080A (ru) 2005-06-10
AU2153599A (en) 1999-06-28
WO1999029308A2 (de) 1999-06-17
US6197780B1 (en) 2001-03-06
HUP0100171A2 (hu) 2003-02-28
HK1037141A1 (en) 2002-02-01
AU751053B2 (en) 2002-08-08
WO1999029308A3 (de) 1999-09-30
DE59801230D1 (de) 2001-09-20
CN1301162A (zh) 2001-06-27
NO324694B1 (no) 2007-12-03
NO20074419L (no) 2000-06-02
CN1152685C (zh) 2004-06-09
KR20010032779A (ko) 2001-04-25

Similar Documents

Publication Publication Date Title
NO20002777L (no) FremgangsmÕte for bekjempelse av fedme
DK1047781T3 (da) IL-18-receptorer
ES2184127T3 (es) Derivados de sulfamato anticonvulsivos utiles para el tratamiento de la obesidad.
EP1231218A3 (en) An appetite-suppressing peptide, its compositions and use
DE69732868D1 (de) Mittel gegen Juckreiz
DK1119371T3 (da) Flt4 (VEGFR-3) som et mål for tumorbilleddannelse og antitumorterapi
DK1632234T3 (da) (S,S)-reboxetin til behandling af kronisk træthedssyndrom
CY1107829T1 (el) Νεες ενωσεις αγωνιστες εξεντινης
DK1094816T3 (da) Biphenylsulfonamider som dobbelte angiotensin-endothelin-receptorantagonister
CL2010000375A1 (es) Compuestos mimeticos de glucocorticoides derivados de hidroxialquilo sustituidos por heterociclos; procedimiento de preparacion; composicion farmaceutica; kit farmaceutico; y uso para el tratamiento de un estado o trastorno seleccionado de diabetes tipo ii, obesidad, hipertension, entre otras (divisional de solicitud 585-03).
DE69727908D1 (de) Tumor-Nekrosis-Faktor verwandter Receptor, TR6
DE69805237D1 (de) Tumornekrose zugehöriger Rezeptor, TR4
TR199701146T1 (xx) N�rotensin resept�rleri �zerinde etkili 1-Fenilpirazol-3-Karboksamidler.
MX225999B (es) Polimorfo antifungico cristalino.
DK1383919T3 (da) Fremgangsmåder og sammensætninger til anvendelse af MHC klasse II-invariant kædepolypeptid som en receptor for makrofag migrationsinhiberede faktor
TR199600359A2 (tr) Adezyon reseptörü antagonistleri.
TR200001290T2 (tr) Estrojen mahrumiyet sendromunu tedavi etmek için yararlı 2-aril-3-aroilbenzo(b) tiofenler.
EP1090994A3 (en) Peptide repeat immunogens
DE59604033D1 (de) Grossformatiger Schamottestein, insbesondere Zinnbadbodenstein
RU2000117857A (ru) Способ борьбы с ожирением
FR2718727B1 (fr) Carbure de tungstène non steochiométrique.
FI974583A0 (fi) Avvattningsfoerfarande och -element i samband med en sellulosatorkmaskin el.dyl.
BR1100506A (pt) Composição para o tratamento de um ser humano sofrendo de um distúrbio intestinal.
ES1035823U (es) Bovedilla perfeccionada.
IT239289Y1 (it) Lumino per sepolcri, immagini votive e simili.

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ABBVIE DEUTSCHLAND GMBH & CO AG, DE

MM1K Lapsed by not paying the annual fees